DR4Death Receptor 4
DR4Direct Repeat 4
DR4Deployment Redeployment, Reintegration, Reconstitution, and Retraining
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
The MxL935xx Telluride family of chips are the world's first DSP SoCs with integrated electro-absorption modulated laser (EA-EML) drivers for 100/400Gbps optical interconnects and breakout mode clocking support for 400Gbps DR4 optical modules.
The research team, from the University of Exeter UK, aimed to investigate whether the increased risk ofT1D that is observed in children and young adults with the DR3 and DR4 genotypes persists into adulthood.
The present study is a pilot one in Benin focusing on the association between T1D and HLA genotyping with the sequence-specific primers of DR3, DR4, DQA1 * 05:01, dQb1 * 02:01, dQb1 * 03:02, and DQB1 * 06:02.
Taking the planting density and basal N amount in the CK mode as a baseline, the four new cropping modes were about 25, 50, 75 and 100% higher in planting density correspondingly with about 25, 50, 75 and 100% less in basal N, respectively (i.e., DR1, DR2, DR3 and DR4 correspondingly).
Most individuals with type I DM carry the HLADR3 and/or DR4 haplotype.
The corresponding region for DR4 and DR5 positively regulates FADD binding, caspase activation, and apoptosis; whereas, the C-terminal tail of Fas receptor has the opposite effect and inhibits binding of FADD to the receptor death domain.
Risk of diabetes is also influenced by [DRB1.sup.*]04 variants and DQ alleles on DR4 haplotypes, with higher risk from [DRB1.sup.*]0405 [odds ratio (OR) = 11.4], [DRB1.sup.*]0401 (OR = 8.4), [DRB1.sup.*]0402 (OR = 3.6), and [DRB1.sup.*]0404 (OR = 1.6), whereas [DRB1.sup.*]0403 is protective (OR = 0.27) (6).
The results of phase II and long-term follow-up treatment of MS patients with dirucotide, published in 2006 in the European Journal of Neurology (EJN), showed that dirucotide delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4, and generally well tolerated.
(Rockville, MD) and University of Michigan (Ann Arbor, MI) have patented Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor receptor family.
To better examine the mechanisms behind this phenomenon, transgenic mice were created that express the human DR4 gene (DRB 1*0401) and are susceptible to autoimmune arthritis induced by type II collagen, a major component of articular cartilage.
However, many of the 22 people in the study who had chronic arthritis had the HLA gene types DR3 and/or DR4. They also had long-lasting symptoms that did not respond well to antibiotic therapy.
This approach showed an association between MS and an HLA-D marker known as DR2 (and less frequently DR4 and DR6).